Several pharmacogenetic-based decision support tools for psychoactive medication
selection are available. However, the scientific evidence of the gene-drug pairs analyzed is …

Aim: To compare pharmacogenetic test predictions with self-reported treatment experience
and side effect tolerability among patients with depression taking psychotherapeutic …

Introduction: Depression is responsible for the most part of the personal and socio-economic
burden due to psychiatric disorders. Since antidepressant response clusters in families …

Major depressive disorder is one of the most prevalent psychiatric disorders, and in spite of
extensive ongoing research, we neither fully understand its etiopathological background …

Major depressive disorder (MDD) is an emergent cause of personal and socio‐economic
burden, both for the high prevalence of the disorder and the unsatisfying response rate of …

Abstract The World Health Organization (WHO) predicts that major depressive disorder
(MDD) will be the second leading cause of death and disability by 2020. Nowadays …

Over 20 years after the initial report of gene variants within the central nervous system
modulating antidepressant response, we are now facing for the first time routine clinical …

Genetic factors play a significant but complex role in antidepressant (AD) response and
tolerability. During recent years, there is growing enthusiasm in the promise of …

Major depressive disorder is connected with high rates of functional disability and mortality.
About a third of the patients are at risk of therapy failure. Several pharmacogenetic markers …

Pharmacogenetic testing is a useful and increasingly widespread tool to assist in
antidepressant prescription. More than ten antidepressants (including tricyclics, selective …